Pfizer secures a $10 billion deal to acquire Metsera, outbidding Novo Nordisk. The move boosts Pfizer’s presence in the fast-growing obesity drug market, signaling a major strategic comeback.

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Pfizer Inc. has agreed to buy Metsera Inc. for $10 billion, surpassing Novo Nordisk in a competitive bidding war. Details of ...

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could ...

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...